A Trial to Learn if Odronextamab is Safe and Well-tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Participants With Follicular Lymphoma (OLYMPIA-1)
Phase: 3
Status: Ongoing
About
A Trial to Learn if Odronextamab is Safe and Well-tolerated and How Well it Works
Compared to Rituximab Combined With Different Types of Chemotherapy for Participants
With Follicular Lymphoma (OLYMPIA-1)
Details
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 X Anti-CD3 Bispecific Antibody Versus Investigator’s Choice in Previously Untreated Participants With Follicular Lymphoma (OLYMPIA-1)
Sponsor: Regeneron Pharmaceuticals
NCT06091254